ArticleOpen medicine (Warsaw, Poland)2025
A discussion on the application of fluorescence micro-optical sectioning tomography in the research of cognitive dysfunction in diabetes.
Article in Open medicine (Warsaw, Poland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This review explores the application value of fluorescence micro-optical sectioning tomography (fMOST) in diabetes-related cognitive dysfunction research, emphasizing its unique capacity to resolve microstructural alterations in neural circuits and vascular networks, thereby offering novel insights into the pathogenesis of type 2 diabetic cognitive impairment. Methods: Existing literature was analyzed to evaluate fMOST's principles and capabilities, including its achievement of whole-brain three-dimensional imaging at sub-micron resolution, simultaneous acquisition of neuronal morphology (soma, dendritic spines, axonal terminals) and vascular networks, and integration with fluorescent labeling to trace prefrontal cortical pyramidal neuron projections under pathological conditions. Results: fMOST technology revealed the critical role of neurovascular coupling dysfunction in diabetic cognitive impairment, demonstrating that interactive damage between neurons and vasculature collectively drives disease progression. In type 2 diabetic models, it identified abnormal synaptic structures in prefrontal/hippocampal pyramidal neurons, vascular network remodeling, and disrupted brain connectivity. Compared to conventional imaging (magnetic resonance imaging/positron emission tomography), fMOST enables concurrent quantitative analysis of synaptic-level neural circuits and microangiopathy, overcoming the resolution limitations of macroscopic imaging. Conclusion: fMOST serves as an indispensable high-precision, multi-scale imaging tool for investigating diabetic cognitive impairment. Future priorities include elucidating dynamic neurovascular unit interactions in diabetic encephalopathy, developing neural circuit-targeted interventions, and advancing interdisciplinary integration to accelerate clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.